Drug intelligence / Profile preview

VAX-PG

Development stage: Discontinued
Lead developer: Vaxcyte
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics

Overview

VAX-PG is a novel therapeutic vaccine candidate developed by Vaxcyte targeting the keystone pathogen responsible for periodontitis, a highly prevalent oral disease. The vaccine leverages a cell-free protein synthesis platform to produce high-fidelity protein antigens that closely mimic those of native pathogens, enabling the development of “tough-to-make” antigens. Its primary goal is to slow or stop the progression of periodontal disease by stimulating an immune response against key bacterial drivers of periodontitis. As of June 2025, it remains in preclinical development[1][2][3].

Brand names: VAX-PG
Other names: VAX-PG

Beyond the preview

Go deeper on VAX-PG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VAX-PG.

Explore the full profile